CD276 as a potential therapeutic target. (A,B) Western blots comparing CD276 levels between cultures exposed to (A) growth factor withdrawal, or (B) shRNA constructs targeting CD276. Densitometry was performed to normalize CD276 signals to their respective loading controls. (C) Limiting dilution analysis for G523 and G583 transfected with either scramble (control) or shRNA constructs targeting CD276 (sh-CD276a and sh-CD276b). Data show mean sphere-forming frequency. Error bars correspond to 95% confidence interval. P-values were determined with ELDA. (D) Limiting dilution analysis for G523 and G583 treated with m276-PBD or vehicle control. Data show mean sphere-forming frequency. Error bars correspond to 95% confidence interval. P-values were determined with ELDA.
